Capsule excision and Ologen implantation for revision after glaucoma drainage device surgery.
BACKGROUND
There is little information available about surgical management after failed glaucoma drainage device (GDD) surgery. We present the outcome of capsule excision after failed GDD surgery compared to capsule excision with additional use of a biodegradable implant (Ologen, version 2) as a placeholder.


METHODS
In an observational comparative case series of 19 patients undergoing excision of the GDD capsule, ten prospectively observed consecutive patients were treated by excision of the capsule, topical mitomycin C application, and implantation of an 10 x 10 x 2 mm-sized Ologen implant (group A) while 9 retrospectively observed consecutive patients were treated by excision of the capsule and topical mitomycin C application alone (group B).


RESULTS
Mean preoperative IOP was 29.4 mmHg for group A and 27.6 mmHg for group B, while mean postoperative IOP at the last follow-up (mean follow-up 11.2 (group A) and 8.6 (group B) months) was 17.3 mmHg for group A and 19.3 mmHg for group B (p > 0.05). Follow-up of the two groups demonstrated a significant difference in success rate (log-rank test, p = 0.04) in favor of group A. No further pressure-reducing surgery was necessary in any of the patients in group A, but it was needed in three of nine patients in group B.


CONCLUSIONS
Although our study has the limitations of small sample size and observational study design, it shows that further investigation is warranted into the potential of Ologen in revision surgery after GDD implantation.
Rosentreter
André
A
Department of Ophthalmology, University of Cologne, Joseph-Stelzmann-Strasse 9, Cologne, Germany. andre.rosentreter@googlemail.com
Mellein
Anne C
AC
Konen
Walter W
WW
Dietlein
Thomas S
TS
D020341:Absorbable Implants; D000328:Adult; D001768:Blister / Q000601:surgery*; D003094:Collagen; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000601:surgery*; D020327:Glaucoma Drainage Implants; D006025:Glycosaminoglycans; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D008297:Male; D033401:Microscopy, Acoustic; D008875:Middle Aged; D011183:Postoperative Complications; D011446:Prospective Studies; D011475:Prosthesis Failure; D019919:Prosthesis Implantation; D012086:Reoperation; D014065:Tonometry, Ocular
D006025:Glycosaminoglycans; C059821:atelocollagen; D003094:Collagen
Ophthalmology. 2006 May;113(5):766-72
16650671
Jpn J Ophthalmol. 2009 Mar;53(2):164-170
19333702
J Glaucoma. 2009 Mar;18(3):220-6
19295377
Arch Ophthalmol. 2009 Apr;127(4):460-4
19365025
Eur J Ophthalmol. 2009 Mar-Apr;19(2):223-30
19253238
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5310-4
17122118
Graefes Arch Clin Exp Ophthalmol. 2008 May;246(5):709-17
18265997
Ophthalmology. 2008 Jul;115(7):1141-7
18164068
Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2404-11
10937547
Aust N Z J Ophthalmol. 1999 Oct;27(5):350-2
10571396
Annu Rev Biophys Bioeng. 1974;3(0):231-53
4607533
Am J Ophthalmol. 2000 Apr;129(4):455-60
10764852
Am J Ophthalmol. 2003 Dec;136(6):994-1000
14644208
Ophthalmology. 1997 Jun;104(6):1004-10
9186442
Graefes Arch Clin Exp Ophthalmol. 2010 Jan;248(1):79-83
19697056
J Glaucoma. 2004 Feb;13(1):38-45
14704542
Surv Ophthalmol. 2005 Jan-Feb;50(1):48-60
15621077
Arch Soc Esp Oftalmol. 2002 Aug;77(8):429-33
12185618